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results did not (n=21) (mMRC .2: 37% vs 5%, p,0.01; CAT.10: 86% vs 57%, p,0.01).
CAPTURE differentiated COPD from no COPD (n=346): SN: 88.0%, SP: 83.9%.
Conclusion: CAPTURE (450/350) may be useful for identifying symptomatic patients with
mild-to-moderate airflow obstruction in need of diagnostic evaluation for COPD.
Keywords: COPD, case-finding, undiagnosed COPD, screening tool, peak expiratory flow

Introduction
COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease
and Exacerbation Risk (CAPTURE™) was developed to identify people with severe,
high-risk undiagnosed COPD, defined as a forced expiratory volume in 1 second
(FEV1) ,60% predicted or exacerbation risk, in primary care settings.1,2 This casefinding method uses five simple patient-completed questions and the selective use of
peak expiratory flow (PEF) to uncover individuals most likely to benefit from diagnosis
and treatment.1–8 The intent is to be as efficient as possible, using PEF selectively based
on questionnaire score and reserving spirometry referrals to the subset of patients
whose results warrant further diagnostic evaluation.1,3,4
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Background: COPD Assessment in Primary Care To Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE™) uses five questions and peak expiratory flow (PEF)
thresholds (males #350 L/min; females #250 L/min) to identify patients with a forced expiratory
volume in 1 second (FEV1)/forced vital capacity (FVC) ,0.70 and FEV1 ,60% predicted or
exacerbation risk requiring further evaluation for COPD. This study tested CAPTURE’s ability
to identify symptomatic patients with mild-to-moderate COPD (FEV1 60%–80% predicted) who
may also benefit from diagnosis and treatment.
Methods: Data from the CAPTURE development study were used to test its sensitivity (SN)
and specificity (SP) differentiating mild-to-moderate COPD (n=73) from no COPD (n=87).
SN and SP for differentiating all COPD cases (mild to severe; n=259) from those without COPD
(n=87) were also estimated. The modified Medical Research Council (mMRC) dyspnea scale and
COPD Assessment Test (CAT™) were used to evaluate symptoms and health status. Clinical
Trial Registration: NCT01880177, https://ClinicalTrials.gov/ct2/show/NCT01880177?term=N
CT01880177&rank=1.
Results: Mean age (+SD): 61 (+10.5) years; 41% male. COPD: FEV1/FVC=0.60 (+0.1), FEV1%
predicted=74% (+12.4). SN and SP for differentiating mild-to-moderate and non-COPD patients
(n=160): Questionnaire: 83.6%, 67.8%; PEF (#450 L/min; #350 L/min): 83.6%, 66.7%; CAPTURE
(Questionnaire+PEF): 71.2%, 83.9%. COPD patients whose CAPTURE results suggested that diagnostic evaluation was warranted (n=52) were more likely to be symptomatic than patients whose
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Although this case-finding method was developed to identify undiagnosed patients with an FEV1% predicted ,60%
or at risk of exacerbation, uncovering symptomatic patients
with FEV1% predicted .60% who might also benefit from
treatment could be advantageous. This study explored the
extent to which CAPTURE identifies these patients.
In its initial testing, CAPTURE was able to differentiate
cases of COPD (FEV1% predicted ,60% or exacerbation
risk) from controls without COPD with a sensitivity (SN) of
89.7% and specificity (SP) of 93.1% (n=273). When subjects
with milder COPD (FEV1% predicted $60% and no/low
exacerbation risk) were included in the control group, testing
the ability of CAPTURE to differentiate the more severe,
high-risk patients from all others, SN was 89.7% and SP was
78.1% (n=346).1 The change in SP indicated that CAPTURE
was classifying some patients with milder airflow obstruction
as cases, a finding interpreted as error because the intent was
to find the more severe, high-risk patients.1 Upon further
reflection, we questioned whether these “misclassified” cases
may represent an additional group of patients who might
also benefit from diagnosis and treatment. Although screening of asymptomatic individuals for undiagnosed COPD is
not recommended,9 identifying symptomatic patients with
mild-to-moderate airflow limitation could be advantageous,
with treated individuals potentially realizing symptomatic,
activity tolerance, and health-status benefits.10–14

Methods
Design
This was a secondary analysis of data from the prospective,
cross-sectional, multisite, case–control study used to
develop CAPTURE.1,15 Specific methods and procedures
for the larger study are presented elsewhere.1 The study
was approved by a central institutional review board (IRB)
(Schulman Associates) and IRBs at each study site (Columbia University, National Jewish Health, Olmsted Medical
Center, University of Kentucky, University of Michigan,
and University of Nebraska Medical Center). Each patient
provided written informed consent before initiating study
procedures. Briefly, for questionnaire development, a pool
of 44 candidate questions and criterion measures were completed by patients identified as cases (n=186; FEV1 ,60% or
$1 exacerbation the previous 12 months) or controls (n=160;
including patients with COPD and FEV1 $60% predicted
and no exacerbations the prior 12 months [n=73] and those
without COPD [n=87]).1 COPD was defined by physician
diagnosis with prescribed pharmacologic maintenance therapy and FEV1/FVC ,0.70. COPD patients with an FEV1%
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predicted of 60%–80% were included in the control group to
optimize the selection of items most sensitive to more severe,
high-risk COPD during random forests analyses. The precision of the questionnaire alone, PEF alone, and CAPTURE
(Questionnaire+PEF) for differentiating cases (n=186) from
non-COPD controls (n=87) was also tested.1
To address the purpose of the current study, analyses were
performed on data from the original control group (n=160),
with cases defined by a diagnosis of COPD, FEV1 $60% predicted, and no exacerbation the prior 12 months (n=73) and
those with no COPD serving as controls (n=87). The entire
dataset (n=346) was used to evaluate CAPTURE across the
full range of COPD (n=259), with patients without COPD
(n=87) serving as controls.

Measures

The CAPTURE Questionnaire
The CAPTURE Questionnaire (Figure 1) comprises five questions assessing the presence/absence of symptoms (breathing
problems and tiring easily), risk exposures, and recent history
of acute respiratory illnesses. Responses are summed to yield
a score ranging from 0 (no to all 5 questions) to 6 (yes to all
questions and .2 respiratory events during the past year).
Scores $2 indicate that further diagnostic assessment for
COPD is warranted. In its initial testing, scores $2 showed
an SN of 95.7% and an SP of 44.4% for differentiating
COPD cases (FEV1% predicted ,60% or exacerbation
risk) from controls (mild/moderate no risk COPD or no
COPD) and an SN of 95.7% and an SP of 67.8% for differentiating cases from those without COPD.1

PEF
PEF is used to increase the precision of case identification. In
the development/validation study, research staff supervised
PEF administration (Vitalograph® AsmaPlan® mechanical PEF
meter; Vitalograph Ltd, Buckingham, UK) during the clinic
visit; each subject performed three maneuvers with the highest
value (L/min) used for analyses. Sex-specific thresholds were
identified to facilitate rapid interpretation in clinical practice
prior to referral for diagnostic spirometry: males ,350 L per
minute (L/min) and females ,250 L/min.1

CAPTURE (Questionnaire+PEF)
Questionnaire scores are used to select the best subset of
patients for PEF testing. Those scoring 0 or 1 on the questionnaire are unlikely to have COPD and can proceed with the
remainder of their clinic visit. Those scoring 5 or 6 (yes to
all items and $1 respiratory events the past year) may have

International Journal of COPD 2018:13
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Figure 1 The Capture™ (COPD assessment in primary care to identify undiagnosed respiratory disease and exacerbation risk) questionnaire.
Notes: Scoring: No =0; Yes =1; Item 5: 0, 1, 2. Scores are summed. © Cornell University, University of Kentucky Research Foundation, and Evidera, Inc. All rights reserved.

undiagnosed disease and can be referred directly to spirometry. Patients scoring 2–4 are clinically equivocal, with PEF
values relative to thresholds used to determine next steps
(spirometry and no spirometry). In the development study,
this two-step process, using the 350/250 L/min thresholds,
improved SN and SP over the questionnaire alone for differentiating cases and controls (89.7% and 78.1%) and cases
and no-COPD controls (89.7% and 93.1%), with the added
advantage of eliminating the need for PEF assessments in
all patients.1

Spirometry

Modified British Medical Research Council dyspnea
scale (mMRC) and COPD Assessment Test (CAT™)

Group differences in sample characteristics were tested
using parametric (normally distributed continuous variables)
and nonparametric (categorical and non-normal continuous
variables) statistics. PEF values were also compared using
analysis of variance, with factors for group, sex, smoking,
age, and group-by-sex interaction.
The precision of the questionnaire, PEF (350/250), and
CAPTURE (Questionnaire+PEF [350/250]) for differentiating patients with and without COPD in this sample was
estimated using SN, SP, overall misclassification error estimates, receiver operator characteristic curves, and area under
the curve.
The SN, SP, and error for PEF alone were examined in
25 mL increments stratified by sex to determine if higher thresholds more accurately differentiated these cases of COPD from
those without COPD, with consideration given to threshold
values that would be easy to recall and apply in clinical settings.

The mMRC16,17 and CAT™18,19 were used to assess patientreported dyspnea and COPD-related health status, respectively. The mMRC is a 5-point (0–4) scale with higher ratings
reflecting more severe breathlessness. CAT scores range from
0 to 40 with higher scores indicating poorer COPD health
status. Patient-level scores ,10 are interpreted as low-impact
COPD, with continued health maintenance interventions
advised, including smoking cessation, vaccination, and exercise. Scores 10–20 are considered moderate-impact COPD
with potential for improvement with treatment, for example,
maintenance therapies, reduction in aggravating factors,
exacerbation prevention, and/or rehabilitation.20 mMRC
.2 and CAT scores .10 are used to categorize patients as
“more symptomatic” under the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines.21

International Journal of COPD 2018:13

Pre-bronchodilator spirometry (FEV1, FEV1% predicted,
and FEV1/forced vital capacity [FVC]) was performed if
spirometry results from the past 5 years were not available.
FEV1/FVC ,0.70 and FEV1 ,80% predicted were considered diagnostic of COPD. All COPD cases met COPD
Foundation Guide spirometry grade 1 requirements (FEV1
$60%; ,80% predicted).7

Analyses
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The best thresholds were then tested with the questionnaire
to determine if new thresholds for males and females would
enhance the precision of CAPTURE in this population.
The extent to which CAPTURE was identifying COPD
patients with dyspnea (mMRC levels .2) and/or poor health
status (CAT scores .10) was tested using Chi-square (χ2)
or Fisher’s exact (cell n ,5) statistics and performed using
the 350/250 and the higher PEF thresholds.
Finally, SN, SP, and error for differentiating the full range
of COPD (n=259) from no COPD (n=87) were assessed for
the questionnaire alone, PEF alone, and CAPTURE using
the 350/250 and higher PEF thresholds.

Results
Sample
Demographic and clinical characteristics of the analytical
sample are shown in Tables 1 and 2. Subjects without COPD
were younger and more likely to be female, employed, and
have a higher educational level than the COPD group.
Of the 73 patients with milder COPD, 23 (31.5%) were
GOLD airflow limitation category 1 (mild) and 50 (68.5%)
were GOLD 2 (moderate).21 COPD patients had significantly
poorer lung function, higher mMRC and CAT scores, and

Table 1 Demographic characteristics by groupa
Characteristic

n=160
COPDb
(n=73)

Age (years)
Mean (SD)
Range
Sex, n (%) male
Ethnic background, n (%)
Not Hispanic or Latino
Racial background, n (%)d
White
Non-white
Employment, n (%)
Employed (full- or part-time)
Not employed
Retired
Disabled
Otherse
Education status, n (%)
High school or less
Some college, vocational training
College degree or more

p-value
No COPDc
(n=87)

65.2 (9.1) 58.1 (10.5)
49–85
40–88
40 (55)
26 (30)

,0.0001

68 (99)

84 (99)

1.000

66 (90)
7 (10)

73 (84)
14 (16)

0.2250a

15 (21)
58 (79)
37 (51)
18 (25)
3 (4)

55 (63)
32 (37)
22 (25)
3 (3)
7 (8)

,0.0001

36 (49)
14 (19)
23 (32)

18 (21)
22 (25)
47 (54)

0.0014

0.0006
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Characteristic

n=160

p-value

COPD
(n=73)

No COPD
(n=87)

2 (3)
48 (66)
23 (32)

51 (59)
28 (32)
8 (9)

b

Smoking history, n (%)
Never or ,100 cigarettes
Former
Current
Spirometry
FEV1, median
Mean (SD)
FEV1% predicted
Mean (SD)
FEV1/FVC, mean (SD)
Peak flow (PEF)

c

,0.0001

2.0
2.1 (0.6)
70.0
74.0 (12.4)
0.6 (0.1)
316.1
(102.86)
mMRC dyspnea scale (0–4 scale)
Median
2
Mode (n, %)
1 (34; 46)
20 (28)
mMRC .2
CAT™ (0–40 scale)
Median
15.0
Mean (SD)
15.6 (8.0)
57 (78)
CAT .10, n (%)
57 (78)
mMRC .2 or CAT .10,
n (%)
20 (28)
mMRC .2 and CAT .10,
n (%)
Comorbid conditions (any),
73 (100)
n (%) yes
Self-report activity on most
days, n (%)
Sit, lie down, walk around 38 (52)
home
Very active or exercise
35 (48)

2.6
2.6 (0.7)
93.0
89.7 (14.6)
0.8 (0.1)
403.5
(109.00)

,0.0001

1
0 (71; 82)
5 (6)

,0.0001

4.0
5.5 (5.4)
13 (15)
15 (17)

,0.0001

3 (3)

,0.0001

76 (87)

0.0010

,0.0001
,0.0001
,0.0001

,0.0001
,0.0001

0.0524
32 (37)
55 (63)

Notes: English-speaking subjects with informed consent and spirometry. bCOPD,
FEV1 60%–80% predicted, and no history of exacerbations .12 months. cNo known
diagnosis or treatment for COPD and FEV1/FVC $0.70.
Abbreviations: CAT, COPD Assessment Test; FEV1, forced expiratory volume
in 1 second; FVC, forced vital capacity; mMRC, modified Medical Research Council
dyspnea scale; PEF, peak expiratory flow.
a

Notes: aEnglish-speaking with informed consent and spirometry. bCOPD, FEV1 60%–
80% predicted, and no history of exacerbations .12 months. cNo known diagnosis
or treatment for COPD and FEV1/FVC $0.70. dSubject self-identified; American
Indian or Alaskan Native (1,1), Asian (0,1), Black or African American (11, 5), and
others (2,0). eOthers: homemaker, unemployed, and not specified.
Abbreviation: FEV1, forced expiratory volume in 1 second.
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Table 2 Clinical characteristics by groupa

were more likely to have a smoking history and one or more
comorbid conditions than those with no COPD. PEF rates
were significantly lower in the COPD group, tested alone and
controlling for age ( p,0.001), sex ( p,0.0001), and smoking
status ( p,0.01) (LS means [95% CI]: COPD [n=73]: 324.3
[301.6; 346.9]; no COPD [n=87]: 403.1 [381.2, 425.1];
F=27.78; p,0.001).

CAPTURE performance
Performance properties of the questionnaire, PEF, and
questionnaire+PEF for these milder COPD cases versus no
COPD are shown in Table 3A and Figure 2A. To assist with
interpretation, results for the more severe high-risk COPD
cases (FEV1 ,60% or risk of exacerbation) versus no COPD
controls from the original development study1 are provided
International Journal of COPD 2018:13
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Milder COPDa (n=73) versus no COPDb (n=87)
Property

Sensitivity (%)
Specificity (%)
Error (%)

Questionnaire

PEFc

Captured

Score .2

350/250
threshold

450/350
threshold

350/250
threshold

450/350
threshold

83.6
67.8
25.0

38.4
90.8
33.1

83.6
66.7
25.6

39.7
93.1
31.3

71.2
83.9
21.9

B
Severe, high-risk COPDa (n=186) versus no COPDb (n=87)1
Property
Sensitivity (%)
Specificity (%)
Error (%)

Questionnaire

PEFc

Captured

Score .2

350/250 threshold

350/250 threshold

95.7
67.8
13.2

88.0
90.8
11.1

89.7
93.1
9.2

C
Full range of COPDa (n=259) versus no COPDb (n=87)
Property

Sensitivity (%)
Specificity (%)
Error (%)

Questionnaire

PEFc

Captured

Score .2

350/250
threshold

450/350
threshold

350/250
threshold

450/350
threshold

92.3
67.8
13.9

73.9
90.8
21.8

94.2
66.7
12.8

75.5
93.1
20.1

88.0
83.9
13.0

Notes: (A) aCOPD, FEV1 60–80% predicted and no history of exacerbations .12 months; bNo known diagnosis or treatment for COPD and FEV1/FVC $ 0.70; cPeak
expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females; dCAPTURE = Questionnaire + PEF. (B) aCOPD, FEV1 , 60% predicted or exacerbation risk;
b
No known diagnosis or treatment for COPD and FEV1/FVC $ 0.70; cPeak expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females; dCAPTURE =
Questionnaire + PEF. (C) aMedical diagnosis and treatment for COPD; FEV1/FVC , 0.70; bNo known diagnosis or treatment for COPD and FEV1/FVC $ 0.70; cPeak
expiratory flow (PEF) rate, liters per minute (L/min), thresholds: males/females (n=344); dCAPTURE = Questionnaire + PEF.
Abbreviations: CAPTURE, COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk; FEV1, forced expiratory volume in 1
second; FVC, forced vital capacity; PEF, peak expiratory flow.

in Table 3B and Figure 2B. Results for all COPD versus no
COPD are shown in Table 3C and Figure 2C. SN analyses
for smoking status are included in Tables S1–S3, with results
suggesting that this was not a confounding factor.

Questionnaire alone
Most COPD patients (61/73; 83.6%) scored $2 on the questionnaire, the threshold for further evaluation of COPD. The
questionnaire was less sensitive differentiating milder COPD
from no COPD (83.6%, Table 3A), relative to its use detecting more severe cases of COPD (95.7%, Table 3B).

PEF alone
PEF (350/250 threshold) was less sensitive differentiating
milder COPD patients from those without COPD (38.4%,
Table 3A) relative to its performance with more severe
cases of COPD (88.0%, Table 3B). Precision estimates for
PEF at 25 L/min increments are shown in Table S4A and B.
Increasing the threshold by 100 L/min (to 450/350 for males/
females) improved the SN of PEF from 38.4% to 83.6%, with
some sacrifice in SP, from 90.8% to 66.7% (Table 3A).
International Journal of COPD 2018:13

CAPTURE (Questionnaire+PEF)
As one might expect given its purpose and development
methods, CAPTURE (PEF 350/250) had substantially lower SN
for detecting patients with milder airflow obstruction (39.7%,
Table 3A) compared to the detection of patients with more
severe, high-risk COPD (89.7%, Table 3B). Using CAPTURE
(PEF 450/350) improved the SN from 39.7% to 71.2%, with
some sacrifice in SP, from 93.1% to 83.9% (Table 3A).

Dyspnea and health status
Most of the milder COPD patients scoring $2 on the questionnaire reported either dyspnea (mMRC $2; n=50/60;
83.3%) or health status impairment (CAT $10/60; n=54/60;
88.5%). For patients with questionnaire scores ,2, most
(9/12; 75%) had an mMRC ,2 (mMRC missing for one
subject) or CAT ,10 (9/12, 75%).
COPD patients whose CAPTURE (PEF 350/250) indicated
the need for further diagnostic evaluation (n=29) were more
likely to report dyspnea (mMRC scores $2, p,0.05) than those
who did not (n=44). There was no difference in health status
(CAT $10) between the two groups (Table S5).
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Figure 2 ROC and AUC by group.
Notes: (A) mildera (n=73) versus No COPDb (n=87); (B) severe, high-risk COPDc (n=186) versus no COPDd (n=87); (C) all COPDe (n=259) versus no COPDf (n=87).
a
COPD, FEV1 60%–80% predicted and no history of exacerbations .12 months. bNo known diagnosis or treatment for COPD and FEV1/FVC $0.70. cFEV1 ,60% or
exacerbation risk. dNo known diagnosis or treatment for COPD and FEV1/FVC $0.70.1 eMedical diagnosis and treatment for COPD; FEV1/FVC ,0.70. fNo known diagnosis
or treatment for COPD and FEV1/FVC $0.70.
Abbreviations: AUC, area under the curve; CAPTURE™, COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk;
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow; ROC, receiver operating characteristics.

Using the higher PEF threshold, COPD patients whose
CAPTURE (PEF 450/350) suggested further evaluation
(n=52) were more likely to be symptomatic (mMRC $2
and CAT $10, p,0.01) than patients whose scores suggested that no further assessment was warranted (n=21)
(Table S3).
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Using CAPTURE to detect a full range
of COPD, mild to severe
As expected, using CAPTURE (PEF 350/250) to differentiate all patients with COPD from those without COPD
alters the precision of the case-finding approach relative
to its original purpose, reducing SN (89.7%–75.5%) and
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increasing error (9.2%–20.1%). Increasing the PEF threshold
improves SN from 75.5% to 88.0% and reduces error
(20.1%–13.0%), with some sacrifice in SP (declines from
93.1% to 83.9%).

Discussion
CAPTURE was designed to help primary care health professionals efficiently identify severe, high-risk undiagnosed
cases of COPD in greatest need of diagnosis and treatment.
Many patients with FEV1 .60% are symptomatic, however,
and may also benefit from treatment.10,11,13,14 The results of
the analyses presented here suggest that CAPTURE can
identify these milder patients with reasonable SN and SP
when PEF thresholds of 450/350 are used. Although more
patients would be referred for diagnostic spirometric testing,
including those without COPD, a substantial portion of those
ultimately diagnosed with COPD are likely to have dyspnea
or health status impairment that may be ameliorated with
treatment.
Given the performance properties of PEF in the current
analyses and previous study, one might be tempted to use PEF
thresholds alone to identify patients in need of spirometry.
However, organizing PEF supplies and performing three
coached maneuvers with all patients in primary care settings,
in addition to other clinic visit assessments, could be challenging. Furthermore, results of PEF provide preliminary
information on airflow obstruction only, with no insight into
exposure, symptoms, or exacerbation risk prior to referral
for diagnostic testing. CAPTURE was designed to balance
efficiency and precision, with the carefully designed questionnaire used as an initial screen and PEF administered to
a subset of patients to yield fewer false positives and reduce
screening costs. The PEF thresholds enable efficient interpretation, with empirically tested quick-recall values (male/
female, moderate to severe: 350/250; mild to moderate:
450/350), although clinicians can also use the observed
value and clinical judgment to determine the need for further
assessment and testing.
Given the relatively high CAT scores in patients with
questionnaire scores $2, one might also ask if the CAT could
be used for case finding. The CAT was developed to facilitate
communication between COPD patients and clinicians,18
covering eight common manifestations of COPD and scores
used to guide treatment. It was neither intended for use in
patients without COPD nor as a screening tool. Following
diagnosis, the CAT can be used to guide treatment and
monitor outcomes.22
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Several limitations of this study should be noted. First, this
was an analysis of data from a subset of subjects participating
in the CAPTURE development study, rather than a large prospective, population-based case-finding study. Results should
be considered exploratory. Second, the COPD and no COPD
groups differed on several sample characteristics. Some of
these differences typify COPD and were expected; however,
differences in demographics (particularly age, sex, and education) and smoking history could have affected the findings.
Although there is no reason to believe that demographic differences altered patient responses to study measures, this must
be recognized as a limitation with further study warranted. SN
analyses in former smokers suggested that results were robust
to smoking history. Third, spirometry values were measured
without bronchodilator administration with the standard FEV1/
FVC diagnostic threshold of ,0.70. Although other diagnostic indicators were also used for group assignment (medical
diagnosis and treatment), the 0.70 threshold can result in
an overestimation of older subjects with airflow limitation.
Once again, further research is needed. Fourth, although
CAPTURE has been tested and performs well identifying
more severe, high-risk cases of COPD in Spanish-speaking
patients,2 sample size precluded testing its performance in
milder symptomatic COPD. Finally, CAPTURE is a tool to
identify patients requiring further evaluation for COPD; it
was not intended to diagnose or evaluate treatment and may
detect problems other than COPD that warrant evaluation. It
was also not intended for use as an outcome measure, with the
CAT best suited to that purpose following diagnosis.

Conclusion
Results of these analyses together with those from the original validation study suggest that CAPTURE can be used to
identify symptomatic patients likely to have airflow limitation
and in need of further clinical evaluation for possible COPD.
Based on the patient’s score on this questionnaire, clinicians
can apply the 350/250 or 450/350 PEF thresholds as they
determine the need for diagnostic spirometry. Further testing
in a large prospective study of this case-finding approach
and its effect on diagnosis, treatment, and patient-centered
outcomes are warranted.
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Supplementary materials
Sensitivity analyses: former smokers
Given the difference in smoking status between the two groups,
SN analyses were performed, testing the performance of the
questionnaire, PEF, and CAPTURE (Questionnaire+PEF
[350/250 and 450/350]) for differentiating COPD and no
COPD in former smokers only (n=56). Demographic and
clinical characteristics of former smokers by group are shown
in Tables S1 and S2. Results are presented in Table S3.
SN, SP, and error were similar to values found in the entire
sample (Table 3), suggesting that smoking history was not
a confounding factor.

Peak expiratory flow (PEF)
Each subject performed three PEF maneuvers using a
Vitalograph® AsmaPlan® mechanical PEF meter (Vitalograph
Ltd, UK), with the highest value (L/min) used for analysis.
Performance properties of PEF at varied thresholds in this
sample stratified by sex are shown in Table S4.

expiratory volume in 1 second (FEV1) ,60% or exacerbation risk. This study assessed the sensitivity (SN), specificity
(SP), and error of this case-finding method for identifying
patients with an FEV1 $60% predicted.
To assess whether the evaluation process was identifying
symptomatic patients, dyspnea (modified Medical Research
Council [mMRC] .2), or health status impairment (COPD
Assessment Test [CAT™] .10) was examined. Table S5 shows
the results of these analyses for the 350/250 and 450/350 PEF
thresholds. In both cases, most of the patients who would be
referred for further diagnostic evaluation reported impaired
health status and a substantial portion reported dyspnea.
Although more patients are referred for further testing when
the higher PEF threshold (450/350) is used, those referred
are more likely to report impaired health status or high levels
of dyspnea compared to those whose scores suggested that
no further testing was warranted. These results suggest that
CAPTURE (PEF 450/350) may be useful for identifying cases
of COPD with an FEV1 .60% predicted, many of whom meet
GOLD guidelines for “more symptomatic” disease.

Clinical characteristics of patients whose
COPD Assessment in Primary Care To
Identify Undiagnosed Respiratory Disease
and Exacerbation Risk (CAPTURE™)
suggests that further diagnostic
evaluation is advised
CAPTURE was developed to identify patients in need of
diagnostic evaluation for undiagnosed COPD and a forced
Table S1 Demographic characteristics of former smokers (N=76) by group
Characteristic
Age (years)
Mean (SD)
Range
Sex, n (%) male
Ethnic background, n (%)
Not Hispanic or Latino
Racial background, n (%)d
White
Non-white
Employment, n (%)
Employed (full- or part-time)
Not employed/otherse
Education status, n (%)
High school or less
Some college, vocational training
College degree or more

Former smokers (N=76)

p-value

COPDb (n=48)

No COPDc (n=28)

67.4 (7.9)
51–85
24 (50)

62.0 (11.1)
40–88
10 (36)

0.0284

46 (98)

28 (100)

1.000

44 (92)
4 (8)

25 (89)
3 (11)

0.7039

10 (21)
38 (79)

10 (21)
38 (79)

0.0052

22 (46)
9 (19)
17 (35)

22 (46)
9 (19)
17 (35)

0.0934

0.2270

Notes: aEnglish-speaking with informed consent and spirometry; bCOPD, FEV1 60%–80% predicted and no history of exacerbations .12 months; cNo known diagnosis
or treatment for COPD and FEV1/FVC $0.70; dSubject self-identified; non-white: American Indian or Alaskan Native (1, 1), Asian (0, 1), Black or African American (1, 2),
others (1, 0). eOthers: homemaker, unemployed, and not specified.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity.
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Table S2 Clinical characteristics of former smokers (N=76) by group
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Characteristic
Spirometry, mean (SD)
FEV1, median
Mean (SD)
FEV1% predicted, median
Mean (SD)
FEV1/FVC
Peak flow (PEF)
mMRC (0–4 scale)
Median
Mode (n, %)
mMRC .2, n (%)
CAT™
Median
Mean (SD)
CAT .10, n (%)
mMRC .2 and CAT .10, n (%)
mMRC .2 or CAT .10, n (%)
Comorbid conditions (any), n (%), yes
Self-report activity on most days, n (%)
Sit, lie down, walk around home
Very active or exercise

COPDb (n=48)

No COPDc (n=28)

p-value

1.9
2.0 (0.6)
68.0
73.5 (13.2)
0.60 (0.06)
320.9 (114.7)

2.4
2.5 (0.7)
85.0
85.0 (17.3)
0.78 (0.06)
396.3 (85.0)

0.0023

1
1 (24, 51)
12 (26)

0
0 (25, 89)
1 (4)

,0.0001

15.0
14.5 (6.6)
38 (79)
12 (26)
38 (79)
48 (100)

5.0
5.5 (4.7)
5 (18)
1 (4)
5 (18)
25 (89)

,0.0001

26 (54)
22 (46)

10 (36)
18 (64)

0.1202

0.0020
,0.0001
0.0035

0.0243

,0.0001
0.0243
,0.0001
0.0466

Notes: aEnglish-speaking subjects with informed consent and spirometry; bCOPD, FEV1 60%–80% predicted and no history of exacerbations .12 months; cno known
diagnosis or treatment for COPD and FEV1/FVC $0.70.
Abbreviations: CAT, COPD Assessment Test; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive
Lung Disease; mMRC, modified Medical Research Council dyspnea scale.

Table S3 Performance of the questionnaire, PEF, and Capturec for differentiating COPDa (n=48) from No COPDb (n=28) in former
smokers (N=76)
Property
Sensitivity (%)
Specificity (%)
Error (%)

Capturec (Questionnaire+PEF)

Questionnaire

PEFc

Score .2

350/250 threshold

450/350 threshold

350/250 threshold

450/350 threshold

87.5
67.9
19.7

33.3
92.9
44.7

81.3
57.1
27.6

39.6
96.4
39.5

70.8
85.7
23.7

Notes: aCOPD, FEV1 60%–80% predicted, and no history of exacerbations .12 months; bno known diagnosis or treatment for COPD and FEV1/FVC $0.70. cPEF rate (L/min),
thresholds: males/females.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow.
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Table S4 Performance properties of PEF thresholds for differentiating milder cases of COPDa from patients without COPDb by sex
Males (n=66)
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Property

PEF threshold (L/min)c

Sensitivity (%)
Specificity (%)
Error (%)

350

375

400

425

450d

475

500

37.5
88.5
42.4

52.5
88.5
33.3

65.0
80.8
28.8

80.0
69.2
24.2

80.0
65.4
25.8

82.5
53.8
28.8

85.0
50.0
28.8

Females (n=94)
Property

PEFc threshold (L/min)

Sensitivity (%)
Specificity (%)
Error (%)

250

275

300

325

350d

375

39.4
91.8
26.6

66.7
86.9
20.2

69.7
85.2
20.2

75.8
80.3
21.3

87.9
67.2
25.5

93.9
42.6
39.4

Notes: aCOPD, FEV1 60%–80% predicted and no history of exacerbations .12 months. bNo known diagnosis or treatment for COPD and FEV1/FVC $0.70. cPEF rate, L/min.
d
Selected threshold.
Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; PEF, peak expiratory flow.

Table S5 Prevalence of dyspnea and health status by Capture™ Responsea in patients with COPDb (N=73)
Characteristic

mMRC .2, n (%)
CAT™ .10, n (%)
mMRC .2 and CAT .10, n (%)

Capture (PEF 350/250)c
Diagnostic testing recommended

Capture (PEF 450/350)d
Diagnostic testing recommended

Yes, n=29 (40%)

No, n=44 (60%)

p-levele

Yes, n=52 (70%)

No, n=21 (30%)

p-levele

12 (43)
26 (90)
12 (43)

8 (18)
31 (70)
8 (18)

0.0227
0.0817
0.0227

19 (37)
45 (86)
19 (37)

1 (5)
12 (57)
1 (5)

0.0042
0.0060
0.0042

Notes: aQuestionnaire+PEF results suggest that further diagnostic evaluation is warranted (yes/no). bCOPD, FEV1 60%–80% predicted, and no history of
exacerbations .12 months. cSensitivity=39.7%; specificity=93.1%; error=31.3% for milder patients versus no COPD. dSensitivity=71.2%; specificity=83.9%; error=21.9% for
milder patients versus no COPD. eChi-square (χ2) or Fisher’s exact (cell n,5).
Abbreviations: CAT, COPD Assessment Test; FEV1, forced expiratory volume in 1 second; mMRC, modified Medical Research Council dyspnea scale; PEF, peak
expiratory flow.
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